RxDoctor Payments Data

Joshua Price, MD

Family Medicine · Moundville, ALNPI 1922661289

Payments from drug & device makers

$2,471in general payments, 2019–2025

Across 126 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$397
  • AbbVie$356
  • AstraZeneca$349
  • Otsuka America Pharmaceutical, Inc.$320
  • Amgen$158
  • Pfizer$132
  • plus $759 from 17 others

What the payments were for

  • Food & beverage$2,471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,471 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$190,359
Medicare patients
318
Services billed
7,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$98,785
JardianceEmpagliflozin94$91,343
EliquisApixaban69$57,157
RybelsusSemaglutide29$39,782
FarxigaDapagliflozin Propanediol46$39,614
JanuviaSitagliptin Phosphate28$33,443
MounjaroTirzepatide16$16,555
MyrbetriqMirabegron16$16,159
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$13,820
Repatha SureclickEvolocumab13$11,752
Tresiba Flextouch U-200Insulin Degludec15$10,436
LinzessLinaclotide11$9,892
Doxepin Hcl23$7,209
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$7,203
Lagevrio (Eua)Molnupiravir13$6,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$397$138,567105 claims
Boehringer IngelheimJardiance$28$91,34394 claims
PfizerEliquis$132$57,15769 claims
MerckJanuvia, Lagevrio (Eua)$17$40,10941 claims
AstraZenecaFarxiga$349$39,61446 claims
Lilly USA, LLCMounjaro$125$16,55516 claims
AbbVieLinzess$356$9,89211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Moundville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →